Delivery Order SPE2DB20D3101-SPE2DB26FQTJ0
- Not listed
- The Defense Logistics Agency (DLA) awarded a $11,073.06 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $21,685.95. This is a firm fixed-price delivery order with no set-aside designation, reflecting open competitive procurement. The order is due for completion by November 4, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,528.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. The contract is a firm fixed price delivery order with an ultimate completion date of November 10, 2025, and was competitively awarded with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,186.32 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500 count) on September 2, 2025, with completion scheduled for September 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical supply will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $7,018.74 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30-count packaging). This competitively awarded, firm fixed-price contract with no set-aside designation was executed on October 24, 2025, with an ultimate completion date of October 27, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $8,606.93. The delivery order, issued on October 14, 2025, with an ultimate completion date of October 15, 2025, represents a non-competitive award under the company's existing contract vehicle with DLA. The place of performance is located at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,822.03 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count), with an ultimate completion date of November 7, 2025. The contract is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor at its Conshohocken, Pennsylvania location. This award represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $3,920.02 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This contract, designated as a firm fixed price delivery order with no set-aside provisions, was competitively awarded on August 13, 2025, with an ultimate completion date of August 14, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $1,707.57 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This competitively awarded, firm fixed price contract was issued on July 15, 2025, with an ultimate completion date of July 16, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB26FQTJ0Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,431.95 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price contract with no set-aside designation was executed on November 6, 2025, with an ultimate completion date of November 7, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. Ondansetron, an antiemetic commonly used in military and veteran healthcare settings, represents one of many pharmaceutical products the contractor delivers under this expansive contract vehicle to support the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 11/6/25 |